arrow
C

Claudia Piombino

istituti clinici scientifici maugeri irccs
H指数:13
被引数:392

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study

BRCA1与BRCA2致病变异或可能致病变异女性中糖耐量受损的比较:一项前瞻性队列研究的结果

2026-05-140
OA
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone Metastases

CDK4/6抑制剂在HR+/HER2-骨转移性乳腺癌患者中的真实世界无进展生存比较

2026-05-010
OA
Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome

患有遗传性乳腺癌和/或卵巢癌综合征的年轻健康女性的生殖潜力降低

2025-03-080
OAAI
A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients

激素敏感型前列腺癌的新型分子特征定义了高风险患者

2025-02-200
OAAI
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (vol 10, 58, 2024)

药物-药物相互作用对abemaciclib在AB-意大利研究的真实世界经验中的临床影响 (第10卷,58卷,2024)

2024-08-020
OAAI
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

在AB-意大利研究的现实世界经验中,药物-药物相互作用对abemaciclib的临床影响

2024-07-173
OAAI
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

新辅助化疗后无病理完全缓解的三阴性乳腺癌患者复发的预测因素

2022-12-019
OAAI
The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study
2021-03-218
OAAI